How It Works
ARA-290 is a short 11-amino-acid peptide modeled on a specific region of erythropoietin (EPO), the hormone best known for signaling red blood cell production. Unlike EPO, ARA-290 is designed to activate only the body's tissue-protective repair pathway rather than the blood-building one, so it does not raise red cell counts. It is thought to work by engaging the innate repair receptor on injured or inflamed tissue, which may help quiet excessive inflammation and encourage repair. Research has explored its role in the health and comfort of small nerve fibers. Dr. Rob decides whether and how it fits your plan based on your labs, history, and goals.
The Science & Mechanism
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide corresponding to the helix B surface region of erythropoietin, a face of the molecule not involved in binding the classical homodimeric EPO receptor. Because of this, it selectively engages the innate repair receptor (IRR), a heteromeric complex formed by the EPO receptor subunit paired with the beta-common receptor (CD131) that is upregulated on tissues under metabolic or inflammatory stress. Signaling through the IRR is described as activating cytoprotective and anti-apoptotic pathways, including JAK2/STAT3, PI3K/Akt, and modulation of NF-kB-driven inflammatory signaling. This is studied as a way to shift injured tissue from a pro-inflammatory state toward resolution and repair, reducing pro-inflammatory cytokine output while supporting cell survival. Critically, ARA-290 does not activate the homodimeric EPO receptor, so it lacks the erythropoietic and pro-thrombotic effects that limit EPO itself. Clinical research has examined ARA-290 in sarcoidosis-associated small fiber neuropathy, where reported outcomes have included changes in neuropathic pain measures and small nerve fiber metrics, alongside its broader investigation as a tissue-protective, immunomodulatory agent.
Potential Benefits
- May support the health and comfort of small nerve fibers
- Studied for its role in engaging the innate repair receptor on stressed tissue
- May help modulate an overactive inflammatory response toward resolution
- Research explores its cytoprotective, anti-apoptotic signaling in injured tissue
- Designed to be non-erythropoietic, avoiding EPO's red-cell and clotting effects
- May complement broader nerve and tissue recovery protocols
Who It May Be Best Suited For
- Individuals focused on nerve health and small fiber comfort
- Those exploring support for a balanced inflammatory response
- People building a structured tissue-repair and recovery protocol
- Clients seeking a non-erythropoietic, tissue-protective peptide option
Important Considerations
ARA-290 is offered as educational, research-informed content and has not been evaluated by the FDA to diagnose, treat, cure, or prevent any disease. Whether it is appropriate for you, and any protocol, route, or duration, is decided one-on-one with Dr. Rob based on your labs, history, and goals. Individual responses vary, and it is used only under direct physician supervision.
